North America Oncology Drugs Market, By Drug Class; By Therapy; By Indication; By Dosage Form; By Distribution Channel; By Country, Trend Analysis, Competitive Landscape & Forecast, 2019-2030

List of Tables

North America Oncology Drugs Market Size Booming at Significant CAGR of 8.26% to Surpass USD 39.22 Billion by 2030

North America Oncology Drugs Market is expanding at a significant growth rate due to advancements in cancer research, increasing prevalence of cancer, rising demand for targeted therapies, rapidly aging population, and improved healthcare infrastructure.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the North America Oncology Drugs Market size by value at USD 34.18 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects the North America Oncology Drugs Market size to expand at a CAGR of 8.26% reaching a value of USD 39.22 billion by 2030. The North America Oncology Drugs Market is propelled by several key factors, including advancements in cancer research and technology, increasing prevalence of cancer, rising demand for personalized medicine, and expanding initiatives for early detection and treatment. Additionally, robust healthcare infrastructure, growing investments in R&D by pharmaceutical companies, and supportive government regulations further stimulate market growth. Moreover, the adoption of innovative therapies such as immunotherapy and targeted therapy, coupled with the aging population and higher awareness about cancer care, drive the demand for oncology drugs in the region, positioning North America as a significant market player in the global oncology landscape.

Opportunity - Development of minimally invasive biopsy techniques

The advancement of minimally invasive biopsy techniques, such as liquid biopsies and image-guided biopsies, significantly impacts the North America Oncology Drugs Market. These techniques offer less invasive means to diagnose and monitor cancer, improving patient comfort and reducing recovery times. With quicker and more accurate diagnoses, oncologists can tailor treatments more effectively, driving demand for innovative oncology drugs. Additionally, these techniques facilitate early detection, leading to timely interventions and potentially better treatment outcomes. Consequently, the market experiences growth as healthcare providers increasingly adopt these advanced biopsy methods to enhance patient care.

Impact of Escalating Geopolitical Tensions on North America Oncology Drugs Market

Escalating geopolitical tensions can significantly impact the North America Oncology Drugs Market, causing disruptions in the supply chain and regulatory challenges. For instance, sanctions imposed on certain countries may hinder the import of crucial pharmaceutical ingredients, affecting drug production. Heightened political instability can also lead to fluctuations in currency exchange rates, impacting drug pricing and affordability for patients. Additionally, trade disputes and tariffs can increase the cost of importing and exporting oncology drugs, potentially leading to reduced access and higher prices. The uncertainty surrounding geopolitical tensions may also discourage investment in research and development, slowing down innovation in the sector. Overall, these factors contribute to an unpredictable and challenging landscape for the North America Oncology Drugs Market, potentially affecting patient care and outcomes.

North America Oncology Drugs Market

Segmental Coverage

North America Oncology Drugs Market - By Drugs

Based on drugs, North America Oncology Drugs Market is divided into Class, Cytotoxic Drugs, Targeted Drugs, and Hormonal Drugs segments. Targeted drugs represent a significant portion of the market due to their precision in attacking cancer cells while minimizing damage to healthy cells, thereby offering potentially more effective and less toxic treatment options for patients. The segment's growth is driven by advancements in targeted therapy research and development, along with increasing adoption by healthcare providers seeking more personalized approaches to cancer treatment.

North America Oncology Drugs Market - By Therapy

Based on therapy, North America Oncology Drugs Market is divided into Chemotherapy, Targeted Therapy, and Immunotherapy segments. The chemotherapy segment is the largest therapy in the North America Oncology Drugs Market. Chemotherapy involves the use of powerful drugs to kill cancer cells and is one of the primary treatment options for various types of cancer. Its widespread application, established efficacy, and long-standing use contribute to its dominance within the North American oncology drugs market. However, targeted therapy and immunotherapy are gaining momentum, offering more precise and effective treatment options for specific types of cancer.

Competitive Landscape

North America Oncology Drugs Market is fiercely competitive. Major companies in the market include Pfizer Inc., Merck & Co., Inc., Bristol Myers Squibb Company, Novartis AG, Roche Holding AG, Johnson & Johnson, AbbVie Inc., Eli Lilly and Company, AstraZeneca PLC, Amgen Inc., Gilead Sciences, Inc., Celgene Corporation, Takeda Pharmaceutical Company Limited, Biogen Inc., and Sanofi S.A. These companies use various strategies, including increasing investments in their R&D activities, mergers, and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in the North America Oncology Drugs Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of North America Oncology Drugs Market. It also highlights the factors driving forecasts of total Market size. The report promises to provide recent technology trends in North America Oncology Drugs Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Product Code: BWC24292

1. Research Framework

1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation

2. Executive Summary

3. North America Oncology Drugs Market Insights

3.1. Industry Value Chain Analysis
3.2. DROC Analysis
- 3.2.1. Growth Drivers
  - 3.2.1.1. Increasing prevalence of cancer
  - 3.2.1.2. Rising awareness of early cancer detection
  - 3.2.1.3. Technological advancements in biopsy techniques
  - 3.2.1.4. Growing adoption of personalized medicine
- 3.2.2. Restraints
  - 3.2.2.1. High cost of biopsies
  - 3.2.2.2. Invasive nature of some biopsy procedures
  - 3.2.2.3. Lack of skilled healthcare professionals
  - 3.2.2.4. Reimbursement challenges
- 3.2.3. Opportunities
  - 3.2.3.1. Development of minimally invasive biopsy techniques
  - 3.2.3.2. Integration of artificial intelligence in biopsy analysis
  - 3.2.3.3. Expansion of liquid biopsy applications
  - 3.2.3.4. Growing demand for personalized cancer treatment plans
- 3.2.4. Challenges
  - 3.2.4.1. Regulatory hurdles
  - 3.2.4.2. Data privacy concerns
  - 3.2.4.3. Ethical considerations around genetic testing
3.3. Technological Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter's Five Forces Analysis
- 3.5.1. Bargaining Power of Suppliers
- 3.5.2. Bargaining Power of Buyers
- 3.5.3. Threat of New Entrants
- 3.5.4. Threat of Substitutes
- 3.5.5. Intensity of Rivalry

4. North America Oncology Drugs Market: Marketing Strategies

5. North America Oncology Drugs Market Overview

5.1. Market Size & Forecast, 2019-2030
- 5.1.1. By Value (USD Billion)
5.2. Market Share and Forecast
- 5.2.1. By Drugs Class
  - 5.2.1.1. Cytotoxic Drugs
  - 5.2.1.2. Targeted Drugs
  - 5.2.1.3. Hormonal Drugs
  - 5.2.1.4. Others
- 5.2.2. By Therapy
  - 5.2.2.1. Chemotherapy
  - 5.2.2.2. Targeted Therapy
  - 5.2.2.3. Immunotherapy
- 5.2.3. By Indication
  - 5.2.3.1. Lung Cancer
  - 5.2.3.2. Stomach Cancer
  - 5.2.3.3. Colorectal Cancer
  - 5.2.3.4. Breast Cancer
  - 5.2.3.5. Prostate Cancer
  - 5.2.3.6. Others
- 5.2.4. By Dosage Form
  - 5.2.4.1. Solid
  - 5.2.4.2. Liquid
  - 5.2.4.3. Injectable
- 5.2.5. By Distribution Channel
  - 5.2.5.1. Hospital Pharmacies
  - 5.2.5.2. Retail Pharmacies
  - 5.2.5.3. Online Pharmacies
- 5.2.6. By Country
  - 5.2.6.1. United States
  - 5.2.6.2. Canada

6. United States Oncology Drugs Market

6.1. Market Size & Forecast, 2019-2030
- 6.1.1. By Value (USD Billion)
6.2. Market Share & Forecast
- 6.2.1. By Drugs Class
- 6.2.2. By Therapy
- 6.2.3. By Indication
- 6.2.4. By Dosage Form
- 6.2.5. By Distribution Channel

7. Canada Oncology Drugs Market

7.1. Market Size & Forecast, 2019-2030
- 7.1.1. By Value (USD Billion)
7.2. Market Share & Forecast
- 7.2.1. By Drugs Class
- 7.2.2. By Therapy
- 7.2.3. By Indication
- 7.2.4. By Dosage Form
- 7.2.5. By Distribution Channel

8. Competitive Landscape

8.1. List of Key Players and Their Offerings
8.2. North America Oncology Drugs Market Share Analysis, 2023
8.3. Competitive Benchmarking, By Operating Parameters
8.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

9. Impact of Escalating Geopolitical Tensions on North America Oncology Drugs Market

10. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

10.1. Pfizer Inc.
10.2. Merck & Co., Inc.
10.3. Bristol Myers Squibb Company
10.4. Novartis AG
10.5. Roche Holding AG
10.6. Johnson & Johnson
10.7. AbbVie Inc.
10.8. Eli Lilly and Company
10.9. AstraZeneca PLC
10.10. Amgen Inc.
10.11. Gilead Sciences, Inc.
10.12. Celgene Corporation
10.13. Takeda Pharmaceutical Company Limited
10.14. Biogen Inc.
10.15. Sanofi S.A.
10.16. Other Prominent Players

11. Key Strategic Recommendations

12. Research Methodology

12.1. Qualitative Research
- 12.1.1. Primary & Secondary Research
12.2. Quantitative Research
12.3. Market Breakdown & Data Triangulation
- 12.3.1. Secondary Research
- 12.3.2. Primary Research
12.4. Breakdown of Primary Research Respondents, By Country
12.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

Product Code: BWC24292

List of Figures

Figure 1 North America Oncology Drugs Segmentation
Figure 2 North America Oncology Drugs Market Value Chain Analysis
Figure 3 Company Market Share Analysis, 2023
Figure 4 North America Oncology Drugs Market Size, By Value (USD Billion), 2019-2030
Figure 5 North America Oncology Drugs Market Share, By Drugs Class, By Value (USD Billion), 2019-2030
Figure 6 North America Oncology Drugs Market Share, By Therapy, By Value (USD Billion), 2019-2030
Figure 7 North America Oncology Drugs Market Share, By Indication, By Value (USD Billion), 2019-2030
Figure 8 North America Oncology Drugs Market Share, By Dosage Form, By Value (USD Billion), 2019-2030
Figure 9 North America Oncology Drugs Market Share, By Distribution Channel, By Value (USD Billion), 2019-2030
Figure 10 North America Oncology Drugs Market Share, By Country, By Value (USD Billion), 2019-2030
Figure 11 United States Oncology Drugs Market Size, By Value (USD Billion), 2019-2030
Figure 12 United States Oncology Drugs Market Share, By Drugs Class, By Value (USD Billion), 2019-2030
Figure 13 United States Oncology Drugs Market Share, By Therapy, By Value (USD Billion), 2019-2030
Figure 14 United States Oncology Drugs Market Share, By Indication, By Value (USD Billion), 2019-2030
Figure 15 United States Oncology Drugs Market Share, By Dosage Form, By Value (USD Billion), 2019-2030
Figure 16 United States Oncology Drugs Market Share, By Distribution Channel, By Value (USD Billion), 2019-2030
Figure 17 Canada Oncology Drugs Market Size, By Value (USD Billion), 2019-2030
Figure 18 Canada Oncology Drugs Market Share, By Drugs Class, By Value (USD Billion), 2019-2030
Figure 19 Canada Oncology Drugs Market Share, By Therapy, By Value (USD Billion), 2019-2030
Figure 20 Canada Oncology Drugs Market Share, By Indication, By Value (USD Billion), 2019-2030
Figure 21 Canada Oncology Drugs Market Share, By Dosage Form, By Value (USD Billion), 2019-2030
Figure 22 Canada Oncology Drugs Market Share, By Distribution Channel, By Value (USD Billion), 2019-2030

List of Tables

Table 1 North America Oncology Drugs Market Size, By Value (USD Billion), 2019-2030
Table 2 North America Oncology Drugs Market Share, By Drugs Class, By Value (USD Billion), 2019-2030
Table 3 North America Oncology Drugs Market Share, By Therapy, By Value (USD Billion), 2019-2030
Table 4 North America Oncology Drugs Market Share, By Indication, By Value (USD Billion), 2019-2030
Table 5 North America Oncology Drugs Market Share, By Dosage Form, By Value (USD Billion), 2019-2030
Table 6 North America Oncology Drugs Market Share, By Distribution Channel, By Value (USD Billion), 2019-2030
Table 7 North America Oncology Drugs Market Share, By Country, By Value (USD Billion), 2019-2030
Table 8 United States Oncology Drugs Market Size, By Value (USD Billion), 2019-2030
Table 9 United States Oncology Drugs Market Share, By Drugs Class, By Value (USD Billion), 2019-2030
Table 10 United States Oncology Drugs Market Share, By Therapy, By Value (USD Billion), 2019-2030
Table 11 United States Oncology Drugs Market Share, By Indication, By Value (USD Billion), 2019-2030
Table 12 United States Oncology Drugs Market Share, By Dosage Form, By Value (USD Billion), 2019-2030
Table 13 United States Oncology Drugs Market Share, By Distribution Channel, By Value (USD Billion), 2019-2030
Table 14 Canada Oncology Drugs Market Size, By Value (USD Billion), 2019-2030
Table 15 Canada Oncology Drugs Market Share, By Drugs Class, By Value (USD Billion), 2019-2030
Table 16 Canada Oncology Drugs Market Share, By Therapy, By Value (USD Billion), 2019-2030
Table 17 Canada Oncology Drugs Market Share, By Indication, By Value (USD Billion), 2019-2030
Table 18 Canada Oncology Drugs Market Share, By Dosage Form, By Value (USD Billion), 2019-2030
Table 19 Canada Oncology Drugs Market Share, By Distribution Channel, By Value (USD Billion), 2019-2030
Table 20 Pfizer Inc. Company Overview
Table 21 Pfizer Inc. Company Overview
Table 22 Merck & Co., Inc. Company Overview
Table 23 Merck & Co., Inc. Company Overview
Table 24 Bristol Myers Squibb Company: Company Overview
Table 25 Bristol Myers Squibb Company: Company Overview
Table 26 Novartis AG Company Overview
Table 27 Novartis AG Company Overview
Table 28 Roche Holding AG Company Overview
Table 29 Roche Holding AG Company Overview
Table 30 Johnson & Johnson Company Overview
Table 31 Johnson & Johnson Company Overview
Table 32 AbbVie Inc. Company Overview
Table 33 AbbVie Inc. Company Overview
Table 34 Eli Lilly and Company: Company Overview
Table 35 Eli Lilly and Company: Company Overview
Table 36 AstraZeneca PLC Company Overview
Table 37 AstraZeneca PLC Company Overview
Table 38 Amgen Inc. Company Overview
Table 39 Amgen Inc. Company Overview
Table 40 Gilead Sciences, Inc. Company Overview
Table 41 Gilead Sciences, Inc. Company Overview
Table 42 Celgene Corporation Company Overview
Table 43 Celgene Corporation Company Overview
Table 44 Takeda Pharmaceutical Company Limited Company Overview
Table 45 Takeda Pharmaceutical Company Limited Company Overview
Table 46 Biogen Inc. Company Overview
Table 47 Biogen Inc. Company Overview
Table 48 Sanofi S.A. Company Overview
Table 49 Sanofi S.A. Company Overview
Table 50 Other Prominent Players Company Overview
Table 51 Other Prominent Players Company Overview

North America Oncology Drugs Market, By Drug Class; By Therapy; By Indication; By Dosage Form; By Distribution Channel; By Country, Trend Analysis, Competitive Landscape & Forecast, 2019-2030

Description

Table of Contents

List of Tables

Table of Contents

1. Research Framework

2. Executive Summary

3. North America Oncology Drugs Market Insights

4. North America Oncology Drugs Market: Marketing Strategies

5. North America Oncology Drugs Market Overview

6. United States Oncology Drugs Market

7. Canada Oncology Drugs Market

8. Competitive Landscape

9. Impact of Escalating Geopolitical Tensions on North America Oncology Drugs Market

10. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

11. Key Strategic Recommendations

12. Research Methodology

List of Figures

List of Tables